Literature DB >> 15978575

Pharmacological characterization of the TRPV1 receptor antagonist JYL1421 (SC0030) in vitro and in vivo in the rat.

Balázs Jakab1, Zsuzsanna Helyes, Angelika Varga, Kata Bölcskei, Arpád Szabó, Katalin Sándor, Krisztián Elekes, Rita Börzsei, Dániel Keszthelyi, Erika Pintér, Gábor Petho, József Németh, János Szolcsányi.   

Abstract

The TRPV1 capsaicin receptor is an integrator molecule on primary afferent neurones participating in inflammatory and nociceptive processes. The present paper characterizes the effects of JYL1421 (SC0030), a TRPV1 receptor antagonist, on capsaicin-evoked responses both in vitro and in vivo in the rat. JYL1421 concentration-dependently (0.1-2 microM) inhibited capsaicin-evoked substance P, calcitonin gene-related peptide and somatostatin release from isolated tracheae, while only 2 microM resulted in a significant inhibition of electrically induced neuropeptide release. Capsazepine (0.1-2 microM), as a reference compound, similarly diminished both capsaicin-evoked and electrically evoked peptide release. JYL1421 concentration-dependently decreased capsaicin-induced Ca(2+) accumulation in cultured trigeminal ganglion cells, while capsazepine was much less effective. In vivo 2 mg/kg i.p. JYL1421, but not capsazepine, inhibited capsaicin-induced hypothermia, eye wiping movements and reflex hypotension (a component of the pulmonary chemoreflex or Bezold-Jarisch reflex). Based on these data JYL1421 is a more selective and in most models also a more potent TRPV1 receptor antagonist than capsazepine, therefore it may promote the assessment of the (patho)physiological roles of the TRPV1 receptor.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15978575     DOI: 10.1016/j.ejphar.2005.05.002

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  15 in total

1.  The TFOS International Workshop on Contact Lens Discomfort: report of the subcommittee on neurobiology.

Authors:  Fiona Stapleton; Carl Marfurt; Blanka Golebiowski; Mark Rosenblatt; David Bereiter; Carolyn Begley; Darlene Dartt; Juana Gallar; Carlos Belmonte; Pedram Hamrah; Mark Willcox
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-10-18       Impact factor: 4.799

2.  Structure-activity relationships of vanilloid receptor agonists for arteriolar TRPV1.

Authors:  Á Czikora; E Lizanecz; P Bakó; I Rutkai; F Ruzsnavszky; J Magyar; R Pórszász; T Kark; A Facskó; Z Papp; I Édes; A Tóth
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

3.  The chimeric approach reveals that differences in the TRPV1 pore domain determine species-specific sensitivity to block of heat activation.

Authors:  Marianthi Papakosta; Carine Dalle; Alison Haythornthwaite; Lishuang Cao; Edward B Stevens; Gillian Burgess; Rachel Russell; Peter J Cox; Stephen C Phillips; Christian Grimm
Journal:  J Biol Chem       Date:  2011-09-12       Impact factor: 5.157

Review 4.  TRPV1: on the road to pain relief.

Authors:  Andrés Jara-Oseguera; Sidney A Simon; Tamara Rosenbaum
Journal:  Curr Mol Pharmacol       Date:  2008-11       Impact factor: 3.339

5.  TRPV1-Targeted Drugs in Development for Human Pain Conditions.

Authors:  Mircea Iftinca; Manon Defaye; Christophe Altier
Journal:  Drugs       Date:  2021-01       Impact factor: 9.546

6.  TRPV1 involvement in inflammatory tissue fibrosis in mice.

Authors:  Yuka Okada; Peter S Reinach; Kumi Shirai; Ai Kitano; Winston W-Y Kao; Kathleen C Flanders; Masayasu Miyajima; Hongshan Liu; Jianhua Zhang; Shizuya Saika
Journal:  Am J Pathol       Date:  2011-06       Impact factor: 4.307

7.  The role of transient receptor potential vanilloid 1 in mechanical and chemical visceral hyperalgesia following experimental colitis.

Authors:  A Miranda; E Nordstrom; A Mannem; C Smith; B Banerjee; J N Sengupta
Journal:  Neuroscience       Date:  2007-08-23       Impact factor: 3.590

8.  TASK1 modulates inflammation and neurodegeneration in autoimmune inflammation of the central nervous system.

Authors:  Stefan Bittner; Sven G Meuth; Kerstin Göbel; Nico Melzer; Alexander M Herrmann; Ole J Simon; Andreas Weishaupt; Thomas Budde; Douglas A Bayliss; Martin Bendszus; Heinz Wiendl
Journal:  Brain       Date:  2009-07-01       Impact factor: 13.501

9.  Characterization of the vasorelaxant mechanisms of the endocannabinoid anandamide in rat aorta.

Authors:  E Herradón; M I Martín; V López-Miranda
Journal:  Br J Pharmacol       Date:  2007-08-20       Impact factor: 8.739

10.  Differential effects of transient receptor vanilloid one (TRPV1) antagonists in acid-induced excitation of esophageal vagal afferent fibers of rats.

Authors:  S Peles; B K Medda; Zhihong Zhang; B Banerjee; A Lehmann; R Shaker; J N Sengupta
Journal:  Neuroscience       Date:  2009-03-24       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.